Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.

Transcriptional Alterations Related to Neuropathology and Clinical Manifestation of Alzheimer’s Disease

Open access

Abstract

Alzheimer's disease (AD) is the most common cause of dementia in the human population, characterized by a spectrum of neuropathological abnormalities that results in memory impairment and loss of other cognitive processes as well as the presence of non-cognitive symptoms. Transcriptomic analyses provide an important approach to elucidating the pathogenesis of complex diseases like AD, helping to figure out both pre-clinical markers to identify susceptible patients and the early pathogenic mechanisms to serve as therapeutic targets. This study provides the gene expression profile of postmortem brain tissue from subjects with clinic-pathological AD (Braak IV, V, or V and CERAD B or C; and CDR ≥1), preclinical AD (Braak IV, V, or VI and CERAD B or C; and CDR = 0), and healthy older individuals (Braak ≤ II and CERAD 0 or A; and CDR = 0) in order to establish genes related to both AD neuropathology and clinical emergence of dementia. Based on differential gene expression, hierarchical clustering and network analysis, genes involved in energy metabolism, oxidative stress, DNA damage/repair, senescence, and transcriptional regulation were implicated with the neuropathology of AD; a transcriptional profile related to clinical manifestation of AD could not be detected with reliability using differential gene expression analysis, although genes involved in synaptic plasticity, and cell cycle seems to have a role revealed by gene classifier. In conclusion, the present data suggest gene expression profile changes secondary to the development of AD-related pathology and some genes that appear to be related to the clinical manifestation of dementia in subjects with significant AD pathology, making necessary further investigations to better understand these transcriptional findings on the pathogenesis and clinical emergence of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0048751

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Hierarchical clustering analysis of CP-AD, P-AD and N samples. Hierarchical clustering was performed by using the expression values from the genes related to AD neuropathology with P≤0.005 (47 transcripts). Each row represents a single gene and each column a sample (dark blue, CP-AD samples; light blue, P-AD samples; yellow, N samples). Red indicates upregulation, green indicates downregulation, and black indicates no change in expression level comparing to reference sample. Cluster support was given by Bootstrap technic (black, 100% of support; grey, 90–100%; blue, 80–90%; green, 70–80%; light yellow, 60–70%; dark yellow, 50–60%; magenta, 0–50%, red, 0%). CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease; N, normal samples (controls).
Figure 1 Hierarchical clustering analysis of CP-AD, P-AD and N samples. Hierarchical clustering was performed by using the expression values from the genes related to AD neuropathology with P≤0.005 (47 transcripts). Each row represents a single gene and each column a sample (dark blue, CP-AD samples; light blue, P-AD samples; yellow, N samples). Red indicates upregulation, green indicates downregulation, and black indicates no change in expression level comparing to reference sample. Cluster support was given by Bootstrap technic (black, 100% of support; grey, 90–100%; blue, 80–90%; green, 70–80%; light yellow, 60–70%; dark yellow, 50–60%; magenta, 0–50%, red, 0%). CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease; N, normal samples (controls).CC BY · PubMed Central
Figure 2 Interaction networks of the significant genes and their interacting partners. (A) Shown are the genes (color nodes) that have, as a function of presence (CP-AD + P-AD) or absence (N) of AD pathology, significantly different correlation of co-expression with their partners. Green nodes indicate genes that are significantly differently expressed between patient groups, while light blue nodes indicate genes that are not significantly differently expressed. Edge colors represent the correlation between a gene and each of its partners. (B) MYC and its interacting partners. Note that the significant genes and their partners form an interconnected network, and despite the interactions involving MYC are not significantly altered, it has a lot of connections, playing an important role as a hub gene. CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease; N, normal samples (controls).
Figure 2 Interaction networks of the significant genes and their interacting partners. (A) Shown are the genes (color nodes) that have, as a function of presence (CP-AD + P-AD) or absence (N) of AD pathology, significantly different correlation of co-expression with their partners. Green nodes indicate genes that are significantly differently expressed between patient groups, while light blue nodes indicate genes that are not significantly differently expressed. Edge colors represent the correlation between a gene and each of its partners. (B) MYC and its interacting partners. Note that the significant genes and their partners form an interconnected network, and despite the interactions involving MYC are not significantly altered, it has a lot of connections, playing an important role as a hub gene. CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease; N, normal samples (controls).CC BY · PubMed Central
Figure 3 Multivariate (three-gene) discriminators for Alzheimer’s disease (AD) classification. (A) Discriminator of CP-AD samples (blue) and P-AD samples (red) using the expression values of PTPRN, ULK2, and HES1 genes. (B) Discriminator of CP-AD samples (blue) and P-AD samples (red) using the expression values of CAPRIN1, ULK2, and RFC2 genes. CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease.
Figure 3 Multivariate (three-gene) discriminators for Alzheimer’s disease (AD) classification. (A) Discriminator of CP-AD samples (blue) and P-AD samples (red) using the expression values of PTPRN, ULK2, and HES1 genes. (B) Discriminator of CP-AD samples (blue) and P-AD samples (red) using the expression values of CAPRIN1, ULK2, and RFC2 genes. CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease.CC BY · PubMed Central
Figure 4 Hypothetical model of the gene expression alterations related to neuropathology and clinical manifestation of Alzheimer’s disease (AD). Gene expression profile changes related to AD pathology are implicated with energy metabolism, oxidative stress, DNA damage and transcriptional regulation. Once established of significant AD pathology, some genes involved with synaptic plasticity, and cell cycle appear to be involved with the clinical outcome of the illness and might represent the molecular mechanisms that underlie the cognitive reserve. CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease.
Figure 4 Hypothetical model of the gene expression alterations related to neuropathology and clinical manifestation of Alzheimer’s disease (AD). Gene expression profile changes related to AD pathology are implicated with energy metabolism, oxidative stress, DNA damage and transcriptional regulation. Once established of significant AD pathology, some genes involved with synaptic plasticity, and cell cycle appear to be involved with the clinical outcome of the illness and might represent the molecular mechanisms that underlie the cognitive reserve. CP-AD, clinic-pathological Alzheimer’s disease; P-AD, pathological/preclinical Alzheimer’s disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 86 references

Research works printed but not linked: 1

  1. C Williams, 2009, Transcriptome analysis of synaptoneurosomes identifies neuroplasticity genes overexpressed in incipient Alzheimer’s disease, PLoS One, 4, e4936, 10.1371/journal.pone.0004936 · DOI · Paper page

Cited by

See all 40

Metadata

Authors
Silva, A. R. T., Grinberg, L. T., Farfel, J. M., Diniz, B. S., Lima, L. A., Silva, P. J. S., Ferretti, R. E. L., Rocha, R. M., Filho, W. J., Carraro, D. M., & Brentani, H.
Affiliations
  • Universidade de São Paulo (BR)
  • AC Camargo Hospital (BR)
Corresponding author
  • Silva, Aderbal R. T.
  • Grinberg, Lea T.
  • Diniz, Breno S.
  • Lima, Leandro A.
  • Silva, Paulo J. S.
  • Rocha, Rafael M.
  • Filho, Wilson Jacob
  • Carraro, Dirce M.
  • Brentani, Helena
Venue
PLoS ONE
Published
2012-11-07
Volume
7
Issue
11
Pages
e48751
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2094058326
Cited by
40
References
86
Citations by year
2024: 3 · 2023: 3 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 2 · 2017: 3 · 2016: 6 · 2015: 3 · 2014: 5 · 2013: 3
FWCI
2.36
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
Fundação de Amparo à Pesquisa do Estado de São Paulo
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, gene expression profiling, postmortem brain, differential gene expression, preclinical Alzheimer's disease, energy metabolism, oxidative stress, DNA damage and repair, cellular senescence, transcriptional regulation, synaptic plasticity, cell cycle, gene classifier, Alzheimer's disease pathogenesis
MeSH terms
Alzheimer Disease, Brain, Dementia, DNA Damage, DNA Repair, Energy Metabolism, Gene Expression Regulation, Cluster Analysis, Cellular Senescence, Oxidative Stress, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Gene Regulatory Networks, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transcriptional Alterations Related to Neuropathology and Clinical Manifestation of Alzheimer’s Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0048751
The paper
Silva, A. R. T., Grinberg, L. T., Farfel, J. M., Diniz, B. S., Lima, L. A., Silva, P. J. S., Ferretti, R. E. L., Rocha, R. M., Filho, W. J., Carraro, D. M., & Brentani, H. (2012). Transcriptional Alterations Related to Neuropathology and Clinical Manifestation of Alzheimer’s Disease. PLoS ONE. https://doi.org/10.1371/journal.pone.0048751

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.